OVERVIEW

6th Annual MarketsandMarkets(MnM) Real-World Evidence and Life Sciences Analytics Conference is organized by MarketsandMarkets Conferences and will be held from Oct 16 - 17, 2023 at Boston, Massachusetts, United States of America.

Description:
Real-world data and real-world evidence are poised to keep making strides in 2023.
The emergence of this pandemic has posed severe financial constraints on pharma-biopharma companies in several countries. In this regard, RWE solutions have proven to be extremely useful, as they allow industrial and academic researchers to monitor patients using digitally connected platforms while assisting to organize and evaluate clinical data for regulatory submissions.

Shifts in healthcare coverage and provision during the pandemic have changed the discovery and reporting of certain outcomes in data and the treated population. This means that disease trends may lead to incorrect interpretations when RWD and RWE are not framed in the context of the pandemic and long-term COVID-19 disease, therapy, and lifestyle changes. Telemedicine and virtual care may also provoke a greater adoption of technologies such as wearables and digital therapeutics, thus accelerating digitalization in the healthcare space and boosting the importance of RWE and AI.

Additionally, with the new guidance by the FDA around data quality and data standards, the stakeholders are seeking to learn about its long-term impact and safety surveillance. This conference will focus on above said significant points and hold discussions on the best practices adopted by various stakeholders with a key takeaway being better decision making.

KEY HIGHLIGHTS:
• Regulatory view around data quality & data standards.
• Leveraging RWE for improving market access.
• The adoption & role of AI & ML in clinical trials.
• Real-world evidence & Digital Health - The expanded role of RWE for digital health.
• Panel Discussion on lessons learned from the recent results of the FDA’s
• pilot program RCT DUPLICATE.
• Real-World Data & Advanced Analytics.
• RWE to inform the decision-making process in rare diseases where there is a lack of evidence.

WHY ATTEND:
• Learn about the recent trends and advancements in Real-World Evidence Generation
• Engage in meaningful discussions with the most prominent industry experts and decision-makers from pharmaceutical and biopharmaceutical companies who will address the most critical
challenges in real-world data and real-world evidence space.
• Opportunity to network and exchange scientific knowledge with expert speakers from leading pharmaceutical companies, global regulators, and solution providers

Additional details will be posted as soon as information is available.